HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Silo enters into commercial evaluation license agreement for next generation liposomes
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bringing next-gen cannabinoid therapeutics to cancer patients
The company is now introducing the product into the India pharmaceutical market.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Subscribe To Our Newsletter & Stay Updated
